WO2010145125A1 - Highly purified human menopausal gonadotropins, method for preparing and uses thereof - Google Patents
Highly purified human menopausal gonadotropins, method for preparing and uses thereof Download PDFInfo
- Publication number
- WO2010145125A1 WO2010145125A1 PCT/CN2009/075277 CN2009075277W WO2010145125A1 WO 2010145125 A1 WO2010145125 A1 WO 2010145125A1 CN 2009075277 W CN2009075277 W CN 2009075277W WO 2010145125 A1 WO2010145125 A1 WO 2010145125A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- purity
- gonadotropin
- dye
- low
- solution
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 54
- 108010057021 Menotropins Proteins 0.000 title abstract 3
- 102000006771 Gonadotropins Human genes 0.000 claims description 48
- 108010086677 Gonadotropins Proteins 0.000 claims description 48
- 239000002622 gonadotropin Substances 0.000 claims description 48
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- 229940094892 gonadotropins Drugs 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 7
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 7
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- -1 oxidized Substances 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 239000002689 soil Substances 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 239000010453 quartz Substances 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 2
- 239000012535 impurity Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 23
- 239000000975 dye Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000000746 purification Methods 0.000 description 7
- 238000010254 subcutaneous injection Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000270295 Serpentes Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000007929 subcutaneous injection Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002023 wood Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
- 229910052753 mercury Inorganic materials 0.000 description 4
- 210000002149 gonad Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
Definitions
- the gonadotropin H ae opa sa o ado op s, H contains fo cesag ho oe FH and eze gho oe LH active ingredients, which are caused by the rest of the protein hormones FH's "and LH, chorionic gonadotropin (cho oc go ado op)" is the same amino acid with 92 amino acids at 1450 D 52 and 78.
- the FH is composed of 11 amino acids. 1800 D where 7 and 24 are the base amino acids, while LH is composed of 121 amino acids at 14800D and 145 amino acids at 22000 390 D
- Bed H should be used for it, or it can be taken from the urine of a woman or DN wood.
- the first generation containing F H is (H ) such as e o o Pe Go a which is a mixture of F H LH ratio 1.
- H the active ingredient in the purity of 40 300 U g protein is only 2 3.
- the rest are egg white. Because of the high protein content, there are potential side effects.
- the method can only be limited to muscle injection.
- High purity (PH) is particularly desirable in the art. It is also of high purity and low content, and does not contain a large amount of protein. Therefore, it does not cause a person to rest and because it can be used to improve the patient by subcutaneous injection.
- This aim is to provide high purity, low purity methods.
- Another purpose of this is to provide high purity obtained by the above method.
- a further object of the present invention is to provide a high purity H compound obtained by the above method.
- a high purity gonadotropin ed H aMe opa sa Go ado op s is provided, the PH HP purity is not less than 95, the HPL content is not 5 HPL, the purity is not less than 96 HPL, and the content is not 4
- the gonadotropin or gonadin or the source of gonadotropin or Hugh.
- the proportion of follicle stimulating hormone F H to form LH is 1 0.5 1.4.
- a method of each of the methods of providing a high purity gonadotropin pH as described above comprising the step of operating a low purity H dye which is not purified and a high purity gonadotropin to a low purity H at 2000 FH 9 protein. the following.
- pH6-1 gives high purity gonadotropins.
- step 3 In another solution from acetic acid, acetic acid, Na H, T s H or phosphoric acid. In the other step, the next step is included in step 3.
- the dye is not separated from bac o B e a ge , ee
- the solid phase of the dye is not precipitated from soil, glass micro, quartz micro, calcium phosphate, oxidized, polypropylene, , , or .
- the dye is not and precipitated from B e epha oseFF or B e epha OSe 6B.
- the compound of the present invention provides an effective amount of the high purity gonadotropin as provided above and the above. Acceptable rest.
- the high purity gonadotropin is not integrated. This product provides high-purity gonadotropins obtained by high-purity, high-purity methods for subcutaneous injection for patient use.
- HPL purity HPL content 5 is currently known to have the highest purity of H and the biological ratio of FH and LH can be within the required solids such as 1 0.1 1 3 .
- Hugh's low purity H dye is not purified and is high Purified gonadotropin.
- low purity means that the organism H below 200 FHU 9 is at 40 50 FHU 9.
- Low purity H can be obtained by methods well known in the art, such as, but not limited to, high soil adsorption in urine, ah, ethanol solution, including 10,000 It can also be obtained from the water. It can also be obtained from this channel.
- the biological ratio of FH and H in low purity H is 1 0.1 3 and the solid content is 1 0.5 1.4.
- the gonads ", " and H” used in this paper can be used. It refers to a protein hormone that is released by life or contains active ingredients of FH and LH. Can be a gonadin or a resting person, or a human source
- follicle stimulating hormone "and FH” can be used to refer to a hormone that promotes or follicles, promotes ovarian ovarian hormones, or can be extracted from the urine of a woman who can be secreted before the break in natural conditions. Got it.
- serotonin and "LH” can be used to refer to a hormone or sputum that is secreted by premenstrual cells and acts on mature ovulation.
- the methods of providing high purity gonadotropins of this invention are the purification of low purity H dyes.
- the method of each high purity gonadotropin in this one includes steps
- a solution containing low purity H is applied to the dye and the supernatant and 2 pH 6 11 to obtain a high purity gonadotropin.
- the dye is not precipitated and can be well known in the art such as, but not limited to, ee, ag.
- Residence B e residence B e epha ose 6B live in a solution of 0.01 5 from acetic acid solution, Na H solution, or T s H solution.
- a solution containing low purity H onto a low-purity H solution on the undegraded B e ephaose is to dissolve low purity H at pH 4 8
- step v Of or sulphuric acid, which is from Na, K, or generally used in the same step in step v and step v
- the low purity H solution in the high purity gonadotropin method provided herein is a solution of low purity H dissolved in 0.01 0.03 acetic acid to obtain a solution containing low purity H. 4 8 high gonads pHMG
- the method can obtain high purity gonadotropin HP content 5 living land HPL content 4
- wood acceptable rest includes various forms and dilutions.
- the woods themselves are not essential active ingredients and are not applied.
- He is known as Re go 'ha ace, which is well known in the art.
- Ca ce ce ack b. Co. .J. 1991) can be found in the above-mentioned acceptable shape.
- the acceptable rest in the compound includes water, water, and ethanol. Sexual things such as, conditions, emulsification, p, etc.
- the compounds can vary from one to the other.
- Oral, topical, non-subcutaneous, intravenous, and intramuscular injection or input or by means of an external device may be administered in one of the following ways. Among them, the subcutaneous injection method.
- the high-purity gonadotropin obtained by the present method can be used for various uncombined administrable applications including (but not limited to), subcutaneous injection, and the like. Apply by subcutaneous injection. The form of application is matched. The amount of application of the active substance is usually 0.01 5 ug kg per day compared with the place of residence 0.05 0. g kg rest 0.2 0. g kg rest.
- the percentage of the vertical break in the present invention is well known in the art, for example, in the 100 ml solution.
- the ratio of H or pH in the present invention refers to how much F H or LH in the milligram protein.
- the method for determining the protein content is based on y or derived methods.
- the HPL purity or HPL content in this specification refers to the percentage of the surface method.
- the method for determining the purity of gonads in the present invention is 2.5
- Each of the high-gonadin 1 uses low-purity H (from Shanghai Bio-Bio Co., Ltd.) as the starting material for p.
- the organism of F is 273 U g LH of the organism 319 U g
- the biological method is determined according to the method of mercury and mercury N in 2005. F H LH organism.
- Each high purity gonadotropin 11 loads 5 LB e epha ose 6B (from E e sha ) (0.02 acetic acid pH 7.0) equilibrated.
- the biological method is determined according to the method of mercury and mercury N in 2005. F H LH organism.
- Protein content determination method Lo y Protein content determination method
- the upper solution was dispensed into 0.75 frozen bottles per bottle.
- the obtained ones were 75 F H 75 LH and 9 lactose per bottle.
- the preferred content of the above-mentioned power is not to limit the wood content of the solid content of the wood content, but also the requirement that the solid wood or the method of any other person to complete the same or the same The history of the exchange will be fixed.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100532746A CN101928342B (en) | 2009-06-18 | 2009-06-18 | High-purity menopausal gonadotropin as well as preparation method and application thereof |
CN200910053274.6 | 2009-06-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010145125A1 true WO2010145125A1 (en) | 2010-12-23 |
Family
ID=43355697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/075277 WO2010145125A1 (en) | 2009-06-18 | 2009-12-03 | Highly purified human menopausal gonadotropins, method for preparing and uses thereof |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR20120042844A (en) |
CN (1) | CN101928342B (en) |
WO (1) | WO2010145125A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015124759A1 (en) * | 2014-02-24 | 2015-08-27 | Altergon Sa | Extraction process to obtain hcg having a high biological activity |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101483165B1 (en) * | 2009-12-22 | 2015-01-15 | 샹하이 테크웰 바이오파마슈티컬 컴퍼니, 리미티드 | Compositions of menopausal gonadotrophins |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1262278A (en) * | 1999-01-26 | 2000-08-09 | Ibsa生物化学研究股份有限公司 | Process for separating and purifying FSH and corpus luteum hormone |
CN1404486A (en) * | 2000-02-22 | 2003-03-19 | 应用研究系统Ars股份公司 | Purified LH (Luteinizing hormone) |
CN1414019A (en) * | 2002-08-14 | 2003-04-30 | 上海天伟生物制药有限公司 | Method of producing high purity postmenopause urine promoted gonadofrophin |
CN1415628A (en) * | 2002-08-14 | 2003-05-07 | 上海天伟生物制药有限公司 | Method for extracting luteinizing hormone from human urine |
CN1587276A (en) * | 2004-07-23 | 2005-03-02 | 南昌市万华生化制品有限公司 | Purifying and producing process for high purity follicle stimulating hormone in urine |
CN101087805A (en) * | 2004-11-09 | 2007-12-12 | 阿雷斯贸易股份有限公司 | Method for purifying FSH |
CN101307103A (en) * | 2007-09-11 | 2008-11-19 | 上海天伟生物制药有限公司 | Purification method of follicle stimulating hormone |
CN101555279A (en) * | 2009-05-19 | 2009-10-14 | 上海天伟生物制药有限公司 | Urinary follicle stimulating hormone with high purity and preparation method thereof |
-
2009
- 2009-06-18 CN CN2009100532746A patent/CN101928342B/en active Active
- 2009-12-03 WO PCT/CN2009/075277 patent/WO2010145125A1/en active Application Filing
- 2009-12-03 KR KR1020127001405A patent/KR20120042844A/en active Search and Examination
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1262278A (en) * | 1999-01-26 | 2000-08-09 | Ibsa生物化学研究股份有限公司 | Process for separating and purifying FSH and corpus luteum hormone |
CN1404486A (en) * | 2000-02-22 | 2003-03-19 | 应用研究系统Ars股份公司 | Purified LH (Luteinizing hormone) |
CN1414019A (en) * | 2002-08-14 | 2003-04-30 | 上海天伟生物制药有限公司 | Method of producing high purity postmenopause urine promoted gonadofrophin |
CN1415628A (en) * | 2002-08-14 | 2003-05-07 | 上海天伟生物制药有限公司 | Method for extracting luteinizing hormone from human urine |
CN1587276A (en) * | 2004-07-23 | 2005-03-02 | 南昌市万华生化制品有限公司 | Purifying and producing process for high purity follicle stimulating hormone in urine |
CN101087805A (en) * | 2004-11-09 | 2007-12-12 | 阿雷斯贸易股份有限公司 | Method for purifying FSH |
CN101307103A (en) * | 2007-09-11 | 2008-11-19 | 上海天伟生物制药有限公司 | Purification method of follicle stimulating hormone |
CN101555279A (en) * | 2009-05-19 | 2009-10-14 | 上海天伟生物制药有限公司 | Urinary follicle stimulating hormone with high purity and preparation method thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015124759A1 (en) * | 2014-02-24 | 2015-08-27 | Altergon Sa | Extraction process to obtain hcg having a high biological activity |
Also Published As
Publication number | Publication date |
---|---|
CN101928342A (en) | 2010-12-29 |
KR20120042844A (en) | 2012-05-03 |
CN101928342B (en) | 2013-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1326636B1 (en) | Vaccine composition | |
WO2004001007A3 (en) | Buffered formulations for concentrating antibodies and methods of use thereof | |
CN1196483C (en) | Compositions for improivng fertility | |
CN1064045C (en) | Thienopyrimidine derivatives, their production and use | |
WO2002020466B1 (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
FR2458538A1 (en) | NONAPEPTIDE AND DECAPEPTITIVE DERIVATIVES OF LUTEINIZING HORMONE-FREE HORMONE, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | |
RU2009139054A (en) | APPLICATION OF LOW TEMPERATURE AND / OR LOW pH IN CELL CULTURE | |
JP2005537234A5 (en) | ||
JP2016520134A (en) | Janus kinase (JAK) inhibitor hydrogen sulfate and method for producing the same | |
EP0031285B1 (en) | Immuno-stimulating preparations based on ribosomal rna of klebsiella pneumoniae and process for the preparation of these rna | |
WO2002085311A3 (en) | Hcg formulation | |
WO2010145125A1 (en) | Highly purified human menopausal gonadotropins, method for preparing and uses thereof | |
Chang et al. | Luteinizing releasing hormone, synthesis and ARG8-analogs, and conformation-sequence-activity relationships | |
Hallick et al. | Vitamin D3-stimulated template activity of chromatin from rat intestine | |
CA2200693A1 (en) | Gp 130 lacking the transmembrane domain | |
TWI343254B (en) | A method of purifying moxidectin through crystallization | |
CN1915986A (en) | High purified tanshinone IIA sodium sulfonate, fabricating method, and preparation | |
JP4257026B2 (en) | Process for selective production of triprenylphenol compounds and their use as pharmaceuticals | |
Franceschi et al. | Ribosomal protein L20 can replace the assembly-initiator protein L24 at low temperatures | |
WO2004078061A3 (en) | Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using luteinizing hormone | |
DE602004017512D1 (en) | NEW PEPTIDE, METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE PEPTIDE | |
CN110272407B (en) | Natural isochromanone compound for reducing blood pressure | |
WO2010111845A1 (en) | A high specific activity human menopausal gonadotropin, preparation method and use thereof | |
JP2008501642A5 (en) | ||
CN104524553B (en) | A kind of long-acting induced ovulation injection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09846039 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 599/CHENP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20127001405 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09846039 Country of ref document: EP Kind code of ref document: A1 |